WebJan 4, 2024 · Oxaliplatin (OXA) and fluorouracil-base adjuvant chemotherapy are the standard treatments for postoperative stage III CRC patients and patients with selective high-risk stage II disease. Recent studies have shown that OXA not only induces tumor cell apoptosis but can also cause immunogenic death. WebJan 16, 2024 · One approach to elicit this transformation involves the use of agents that induce immunogenic cell death (ICD) within the tumor. A limited number of cytotoxic agents (e.g., anthracyclines, oxaliplatin, radiation therapy, oncolytic viruses) have been shown to induce ICD ( 21 – 28 ).
Chemotherapeutic drug-induced immunogenic cell death for …
WebAccumulating evidence suggests that chemotherapeutic agents, including oxaliplatin and doxorubicin, not only mediate direct cytotoxicity in tumor cells but also induce … WebNumerous anti-cancer drugs have been shown to promote tumour immunogenicity through mechanisms such as immunogenic cell death and modulation of tumour cell surface regulators . Both 5-fluorouracil (5-FU) and oxaliplatin (OXA), chemotherapeutics used in the first-line treatment of colorectal cancer, increase tumour immunogenicity when used in ... design with emphasis
Trial watch: chemotherapy-induced immunogenic cell death in …
WebOxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy Our data indicate that oxaliplatin … WebSep 1, 2024 · Thus, several major chemotherapeutic agents, including anthracyclines and oxaliplatin, induced “immunogenic cell death” (ICD), meaning that they stress and kill cancer cells in such a way that they become recognizable to the immune system ( 2 ). WebApr 7, 2024 · Accumulating evidence suggests that chemotherapeutic agents, including oxaliplatin and doxorubicin, not only mediate direct cytotoxicity in tumor cells but also induce immunogenic cancer cell death to stimulate a powerful anti-cancer immune response in the tumor microenvironment. ... Despite some clinical failures and … chuck fields